Top

Inflammation Research

Published in:

01-04-2014 | Review

Linking GATA-3 and interleukin-13: implications in asthma

Authors: Sheikh Rayees, Fayaz Malik, Syed Imran Bukhari, Gurdarshan Singh

Published in: Inflammation Research | Issue 4/2014

Abstract

Introduction

Asthma is one of the serious global health problems and cause of huge mortality and morbidity. It is characterized by persistent airway inflammation, airway hyperresponsiveness, increased IgE levels and mucus hypersecretion. Asthma is mediated by dominant Th2 immune response, causing enhanced expression of Th2 cytokines. These cytokines are responsible for the various pathological changes associated with allergic asthma.

Materials and methods

The role of Th2 cells in the pathogenesis of the asthma is primarily mediated through the cytokine IL-13, also produced by type 2 innate lymphoid cells, that comes under the transcriptional regulation of GATA3. In this review we will try to explore the link between IL-13 and GATA3 in the progression and regulation of asthma and its possible role as a therapeutic target.

Conclusion

Inhibition of GATA3 activity or blockade of GATA3 expression may attenuate the interleukin-13 mediated asthma phenotypes. So, GATA3 might be a potential therapeutic target for the treatment of allergic asthma.

Walsh GM, McDougall CM. The resolution of airway inflammation in asthma and COPD. In: Rossi AG, Sawatzky D, editors. Progress in inflammation research. Basel: Birkhauser Verlag A.G; 2007. p. 159–191.

Braman SS. The global burden of asthma. Chest. 2006;130:4S–12S.PubMed

McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care. 2012;185:612–9.

Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372:1107–19.PubMed

Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. Lancet. 2002;360:1313–22.PubMed

Barnes PJ. Pathophysiology of asthma. Eur Respir Mon. 2003;8:84–113.

Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, Jeffery PK. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med. 2003;167:78–82.PubMed

Allen D, Adinoff MD, Roger J, Hollister MD. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983;309:265–8.

Sont JK, Han J, van-Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996;51:496–502.PubMedCentralPubMed

10.

Silverman AB. Treatment of steroid dependent asthmatics, US 5405842 A. 1995; 08/187, 915.

11.

Comet R, Domingo C, Larrosa M, Morón A, Rué M, Amengual MJ, Marín A. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med. 2006;100:411–9.PubMed

12.

Haldar P, Brightling CE, Hargadon B. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–84.PubMed

13.

Kraft M. Asthma phenotypes and interleukin-13—moving closer to personalized medicine. N Engl J Med. 2011;365:1141–4.PubMed

14.

Antoniu SA, Pitrakinra A. Dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Invest Drugs. 2010;11:1286–94.

15.

Woodruff PG, Modrek B, et al. T-helper type 2—driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95.PubMedCentralPubMed

16.

Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S, O’Connor BJ. Selective Inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med. 2007;176:988–93.PubMed

17.

Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA. 2007;2:15858–63.

18.

Wochnik GM, Rüegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 2005;280:4609–16.PubMed

19.

Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology. 2000;141:4107–13.PubMed

20.

Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A. New drugs targeting Th2 lymphocytes in asthma. J Occup Med Toxicol. 2008;3:1–6.

21.

Stephen TH, Riccardo P. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8:218–30.

22.

Morrisey EE, Ip HS, Lu MM, Parmacek MS. GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol. 1996;177:309–22.PubMed

23.

Arceci RJ, King AA, Simon MC, Orkin SH, Wilson DB. Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart. Mol Cell Biol. 1993;13:2235–46.PubMedCentralPubMed

24.

Ho IC, Vorhees P, Marin N, Oakley BK, Tsai SF, Orkin SH, Leiden JM. Human GATA-3: a lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J. 1991;10:1187–92.PubMedCentralPubMed

25.

Oosterwegel M, Timmerman J, Leiden J, Clevers H. Expression of GATA-3 during lymphocyte differentiation and mouse embryogenesis. Dev Immunol. 1992;3:1–11.PubMedCentralPubMed

26.

Samson SI, Richard O, Tavian M, Ranson T, Vosshenrich CA, Colucci F, Buer J, Grosveld F, Godin I, Di-Santo JP. GATA-3 promotes maturation. IFN-γ production and liver-specific homing of NK cells. Immunity. 2003;19:701–11.PubMed

27.

O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8:275–83.PubMed

28.

Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, Afkarian M, Murphy TL. Signaling and transcription in T helper development. Annu Rev Immunol. 2000;18:451–94.PubMed

29.

Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev. 2000;14:1693–711.PubMed

30.

Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–56.PubMed

31.

Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175–90.PubMed

32.

Caramori G, Lim S, Ito K, Tomita K, Oates T, Jazrawi E, Chung KF, Barnes PJ, Adcock IM. Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. Eur Respir J. 2001;18:466–73.PubMed

33.

Wohlfert EA, Grainger JR, Bouladoux N. GATA3 controls Foxp3⁺ regulatory T cell fate during inflammation in mice. J Clin Invest. 2011;121:4503–15.PubMedCentralPubMed

34.

Usui T, Nishikomori R, Kitani A, Strober W. GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12R beta2 chain or T-bet. Immunity. 2003;18:415–28.PubMed

35.

Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC, Murphy KM. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity. 1998;9:745–55.PubMed

36.

Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest. 1999;104:985–93.PubMedCentralPubMed

37.

McLane MP, Haczku A, Van-de-Rijn M, Weiss C, Ferrante V, MacDonald D, McLane MP, Haczku A, Van-de-Rijn M, Weiss C, Ferrante V, MacDonald D, Renauld JC, Nicolaides NC, Holroyd KJ, Levitt RC. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyper responsiveness in transgenic mice. Am J Respir Cell Mol Biol. 1998;19:713–20.PubMed

38.

Yao X, Zha W, Song W, et al. Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping. Biochem Biophys Res Commun. 2012;417:996–1001.PubMed

39.

Jee YK, Gilmour J, Kelly A, et al. Repression of interleukin-5 transcription by the glucocorticoid receptor targets gata3 signaling and involves histone deacetylase recruitment. J Boil Chem. 2005;280:23243–50.

40.

Grogan JL, Mohrs M, Harmon B, Lacy DA, Sedat JW, Locksley RM. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity. 2001;14:205–15.PubMed

41.

Yamane H, Zhu J, Paul WE. Independent roles for IL-2 and GATA-3 in stimulating naive CD4 + T cells to generate a Th2-inducing cytokine environment. J Exp Med. 2005;202:793–804.PubMedCentralPubMed

42.

Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao A. TH cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol. 2002;3:643–51.PubMed

43.

Lee GR, Fields PE, Flavell RA. Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. Immunity. 2001;14:447–59.PubMed

44.

Ouyang W, Löhning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, Murphy KM. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity. 2007;12:27–37.

45.

Amsen D, Antov A, Jankovic D, Sher A, Radtke F, Souabni A, Busslinger M, McCright B, Gridley T, Flavell RA. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity. 2007;27:89–99.PubMedCentralPubMed

46.

Fang TC, Yashiro-Ohtani Y, Bianco CD, Knoblock DM, Blacklow SC, Pear WS. Notch directly regulates Gata3 expression during T helper 2 cell differentiation. Immunity. 2007;27:100–10.PubMedCentralPubMed

47.

Asnagli H, Afkarian M, Murphy KM. Cutting edge: identification of an alternative GATA-3 promoter directing tissue-specific gene expression in mouse and human. J Immunol. 2002;168:4268–71.PubMed

48.

Zhu J, Cote-Sierra J, Guo L, Paul WE. Stat5 activation plays a critical role in Th2 Differentiation. Immunity. 2003;19:739–48.PubMed

49.

Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, Zhu J, Paul WE. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci. 2004;101:3880–5.PubMedCentralPubMed

50.

Piper Edward, Brightling Christopher, Niven Robert, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330–8.PubMedCentralPubMed

51.

Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011;183:1007–14.PubMed

52.

Pueringer RJ, Hunninghake GW. Inflammation and airway reactivity in asthma. Am J Med. 1992;92:32S–8S.PubMed

53.

White MV. Nasal cholinergic hyper responsiveness in atopic subjects studied out of season. J Allergy Clin Immunol. 1993;92:278–87.PubMed

54.

Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261–3.PubMedCentralPubMed

55.

Karp MW, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–61.PubMed

56.

Haczku A, Cao Y, Vass G, Kierstein S, Nath P, Atochina-Vasserman EN, Scan-lon ST, Li L, Griswold DE, Chung KF, Poulain FR, Hawgood S, Beers MF, Crouch EC. IL-4 and IL-13 form a negative feedback circuit with surfactant protein-D in the allergic airway response. J Immunol. 2006;176:3557–65.PubMed

57.

Madan T, Reid KB, Singh M, Sarma PU, Kishore U. Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigates. J Immunol. 2005;174:6943–54.PubMed

58.

Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyff RH, Umetsu DT. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol. 2001;167:4668–75.PubMed

59.

Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K, Umeshita R, Abe Y, Braun S, Yamashita T, Roberts MH, Sugimoto R, Arima K, Arinobu Y, Yu B, Kruse S, Enomoto T, Dake Y, Kawai M, Shimazu S, Sasaki S, Adra CN, Kitaichi M, Inoue H, Yamauchi K, Tomichi N, Kurimoto F, Hamasaki N, Hopkin JM, Izuhara K, Shirakawa T, Deichmann KA. Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet. 2000;9:549–59.PubMed

60.

Eum SY, Maghni K, et al. IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2005;288:576–84.

61.

Walsh GM. Novel cytokine-directed therapies for asthma. Discov Med. 2011;11:283–91.PubMed

62.

Fallon PG, Emson CL, Smith P, McKenzie AN. IL-13 over expression pre-disposes to anaphylaxis following antigen sensitization. J Immunol. 2001;166:2712–6.PubMed

63.

McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, Zurawski G, Murray R, Grencis R, McKenzie AN. Impaired development of Th2 cells in IL-13-deficient mice. Immunity. 1998;9:423–32.PubMed

64.

Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol. 2000;165:108–13.PubMed

65.

Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, Balhorn A, Donaldson DD, Dakhama A, Gelfand EW. The role of IL-13 in established allergic airway disease. J Immunol. 2002;169:6482–9.PubMed

66.

Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC, Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface anti-gen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol. 1996;157:1678–83.PubMed

67.

Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, Foster PS, Rothenberg ME. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol. 2001;108:594–601.PubMed

68.

Lam KP, Chu YT, Lee MS, Chen HN, Wang WL, Tok TS, Chin YY, Chen SC, Kuo CH, Hung CH. Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells. Pediatr Allergy Immunol. 2011;22:431–9.PubMed

69.

Tomasiak-Łozowska MM, Bodzenta-Łukaszyk A, Tomasiak M, Skiepko R, Zietkowski Z. The role of interleukin 13 and interleukin 5 in asthma. Postepy Hig Med Dosw. 2010;19:146–55.

70.

Taku K, Kiyosh T. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21:1303–9.

71.

Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts implication in asthma. J Clin Invest. 1998;101:2129–39.PubMedCentralPubMed

72.

Fulkerson PC, Fischetti CA, Hassman LM, Nikolaidis NM, Rothenberg ME. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol. 2006;35:337–46.PubMedCentralPubMed

73.

Blease K, Schuh JM, Jakubzick C, Lukacs NW, Kunke SL, Joshi BH, et al. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol. 2002;160:481–90.PubMedCentralPubMed

74.

Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy. 2002;32:1104–11.PubMed

75.

Vercelli D, Jabara HH, Arai KI, Geha RS. Induction of human IgE synthesis requires interleukin 4 and T/B interactions involving the T cell receptor/CD3 complex and MHC class II antigens. J Exp Med. 1989;169:1295–307.PubMed

76.

Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, Zurawski G. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci. 1993;90:3730–4.PubMedCentralPubMed

77.

Punnonen J, Cocks BG, De Vries JE. IL-4 induces germ-line IgE heavy chain gene transcription in human fetal pre-B cells. Evidence for differential expression of functional IL-4 and IL-13 receptors during B cell ontogeny. J Immunol. 1995;155:4248–54.PubMed

78.

Whittaker L, Niu N, Temann UA, Stoddard A, Flavell RA, Ray A. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol. 2002;27:593–602.PubMed

79.

Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8:885–9.PubMed

80.

Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3- kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285:730–9.

81.

Finkelman FD, Yang M, Perkins C, Schleifer K, Sproles A, Santeliz J. Suppressive effect of IL-4 on IL-13-induced genes in mouse lung. J Immunol. 2005;174:4630–8.PubMed

82.

Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol. 2008;9:25–33.PubMedCentralPubMed

83.

Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Ann Rev Immunol. 2004;22:789–815.

84.

Hohlfeld JM, Erpenbeck VJ, Krug N. Surfactant proteins SP-A and SP-D as modulators of the allergic inflammation in asthma. Pathobiology. 2002;70:287–92.PubMed

85.

Aman MJ, Tayebi N, Obiri NI, et al. cDNA cloning and characterization of the human interleukin 13 receptor αchain. J Biol Chem. 1996;271:29265–70.PubMed

86.

Miloux B, Laurent P, Bonnin O, et al. Cloning of the human IL-13Rα1 chain and reconstitution with the IL4Rα of a functional IL-4/IL-13 receptor complex. FEBS Lett. 1997;401:163–6.PubMed

87.

Donaldson DD, Whitters MJ, Fitz LJ. The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol. 1998;161:2317–24.PubMed

88.

Homer RJ, Zheng T, Chupp G, He S, Zhu Z, Chen Q, Ma B, Hite RD, Gobran LI, Rooney SA, Elias JA. Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure. Am J Physiol Lung Cell Mol Physiol. 2002;283:52–9.

89.

Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779–88.PubMedCentralPubMed

90.

Zhou M, Ouyang W. The function role of GATA-3 in Th1 and Th2 Differentiation. Immunol Res. 2003;28:25–37.PubMed

91.

Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it. J Cell Physiol. 2010;222:42–9.PubMedCentralPubMed

92.

Rothenberg EV, Moore JE, Yui MA. Launching the T-cell lineage developmental programme. Nat Rev Immunol. 2008;8:9–21.PubMedCentralPubMed

93.

Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 2009;9:125–35.PubMedCentralPubMed

94.

Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and IL-4 locus accessibility. Ann Rev Immunol. 2006;24:607–56.

95.

Nakayama T, Yamashita M. Initiation and maintenance of Th2 cell identity. Curr Opin Immunol. 2008;20:265–71.PubMed

96.

Kishikawa H, Sun J, Choi A, Miaw SC, Ho IC. The cell type specific expression of the murine IL-13 gene is regulated by GATA-3. J Immunol. 2001;167:4414–20.PubMed

97.

Maurice D, Hooper J, Lang G, Weston K. c-Myb regulates lineage choice in developing thymocytes via its target gene Gata3. EMBO J. 2007;26:3629–40.PubMedCentralPubMed

98.

Pai SY. Distinct structural requirements of GATA-3 for the regulation of thymocyte and Th2 cell differentiation. J Immunol. 2008;180:1050–9.PubMed

99.

Zhao X. Interaction between GATA-3 and the transcriptional co regulator Pias1 is important for the regulation of Th2 immune responses. J Immunol. 2007;179:8297–304.PubMed

100.

Zurawski G, de Vries JE. Interleukin 13, an interleukin-4 like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today. 1994;15:19–26.PubMed

101.

Woerly G, Lacy P, Younes AB. Human eosinophils express and release IL-13 following CD28-dependent activation. Jour Leukoc Biol. 2002;72:769–79.

102.

Akbari O, Stock P, Meyer E. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med. 2003;9:582–8.PubMed

103.

Guo L, Wei G, Zhu J, Liao W, Leonard WL, Zhao K, Paul W. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. PNAS. 2009;106:13463–8.PubMedCentralPubMed

104.

Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12:631–8.PubMedCentralPubMed

105.

Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12:1055–62.PubMed

106.

Klein-Wolterink RG, Serafini N, van Nimwegen M, et al. Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc Natl Acad Sci USA. 2013;110:10240–1025.PubMedCentralPubMed

107.

Zhang DH, Yang L, Cohn L. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant negative mutant of GATA-3. Immunity. 1999;11:473–82.PubMed

108.

Takemoto N, Kamogawa Y, Jun-Lee H, Kurata H, Arai KI. A O’Garra, N Arai, S Miyatake, Chromatin remodeling at the IL-4/IL-13 intergenic regulatory region for Th2-specific cytokine gene cluster. J Immunol. 2000;165:6687–91.PubMed

109.

Lee HJ, Takemoto N, Kurata HY, et al. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med. 2000;192:105–15.PubMedCentralPubMed

110.

Cecile LB, Cecelia DT, Iman M, Paul-Henri R, Max-Audit I. Interleukin-13 gene expression is regulated by gata-3 in T cells. J Biol Chem. 2002;277:18313–21.

111.

Zhang DH, Yang L, Ray A. Differential responsiveness of the IL-5 and IL-4 genes to transcription factor GATA-3. J Immunol. 1998;161:3817–21.PubMed

112.

Yamashita M, Ukai-Tadenuma M, Kimura M. Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus. J Biol Chem. 2002;277:42399–408.PubMed

113.

Maneechotesuwan K, Xin Y, Ito K, et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol. 2007;178:2491–8.PubMed

114.

Nakamura Y, Hoshino M. Th2 cytokines and associated transcription factors as therapeutic targets in asthma. Curr Drug Targets Inflamm Allergy. 2005;4:267–70.PubMed

Title: Linking GATA-3 and interleukin-13: implications in asthma
Authors: Sheikh Rayees
Fayaz Malik
Syed Imran Bukhari
Gurdarshan Singh
Publication date: 01-04-2014
Publisher: Springer Basel
Published in: Inflammation Research / Issue 4/2014
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0700-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

The significance of YKL-40 protein in liver fibrosis

Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells

Intracranial injection of recombinant stromal-derived factor-1 alpha (SDF-1α) attenuates traumatic brain injury in rats

Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis

Tissue factor inflammatory response regulated by promoter genotype and p38 MAPK in neonatal vs. adult microvascular endothelial cells

Correlation of human S100A12 (EN-RAGE) and high-sensitivity C-reactive protein as gingival crevicular fluid and serum markers of inflammation in chronic periodontitis and type 2 diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials